Strategies for Equitable Access in Hidradenitis Suppurativa

Panelist discusses how rapid access clinics could revolutionize HS patient care by providing swift, comprehensive diagnostic pathways, integrating multidisciplinary expertise, and enabling early intervention. Strategies for equitable access include telemedicine, mobile diagnostic units, community health worker training, sliding-scale pricing, and partnerships with local health care providers to overcome geographical and economic barriers in underserved regions.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

Now Viewing

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models

EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence

EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

EP: 12.Navigating HS Management: The Patient Journey

EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement

EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes

Video content above is prompted by the following:

• In what ways could rapid access clinics serve as a model for early diagnosis and coordinated care for HS patients?
• What strategies can be employed to ensure equitable access to diagnostic services for patients in underserved areas?

Related Videos

Related Content

Advertisement

April 1st 2025

MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe

Maggie L. Shaw

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

Speech Recognition Tools May Boost Clinician Documentation Efficiency

Brooke McCormick

Documentation efficiency was higher among younger and male clinicians.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

March 26th 2025

PAH Therapies Improve Outcomes in PH-ILD

Maggie L. Shaw

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.

Related Content

Advertisement

April 1st 2025

MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe

Maggie L. Shaw

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

Speech Recognition Tools May Boost Clinician Documentation Efficiency

Brooke McCormick

Documentation efficiency was higher among younger and male clinicians.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

March 26th 2025

PAH Therapies Improve Outcomes in PH-ILD

Maggie L. Shaw

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.